Factor Model (net +1.4)
Factor Model
net +1.4Cantor Fitzgerald starts STTK Overweight
Watch: Watch FDA trial readouts on DR3 and TL1A programs as catalysts for valuation re-rating.
Cantor Fitzgerald initiated coverage of Shattuck Labs with an Overweight rating on April 27, 2026. The stock jumped over 800% in the last 12 months, driven by enthusiasm for its DR3 and TL1A antibody programs. H.C. Wainwright raised the price target sharply from $6 to $18, reflecting higher success probabilities for SL-325 now at 15%. Multiple insiders, including Orbimed Advisors and Ashiya Mona, bought $5.47M of shares at $0.87, continuing a strong insider buying trend.
Strong insider buying and upgraded coverage indicate high conviction in the company's pipeline and growth potential, signaling confidence in future share price appreciation.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when STTK changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.